Gurnet Point Capital, the $2 billion health care and life science investment firm that recruited former Sanofi CEO Christopher Viehbacher earlier this year, has committed $600 million to one of Viehbacher's pet projects: a company called Boston Pharmaceuticals Inc. that will bridge the valley of death between promising early-stage drugs and big pharma's aversion to R&D risk. [See Deal]
Boston Pharmaceuticals: A New Model To De-Risk Drugs
Christopher Viebacher's new venture Boston Pharmaceuticals was established with enough capital - $600 million - to scour thousands of Phase-I ready programs and build a portfolio of 20 to 25 early-stage drug candidates that it will attempt to de-risk then sell or license to interested partners